



## Molecular Mechanism for Coronavirus Infection

Guest Editor:

### Dr. Qibin Geng

Department of Pharmacology,  
University of Minnesota,  
Minneapolis, MN 55455, USA

Deadline for manuscript  
submissions:

**closed (31 October 2023)**

### Message from the Guest Editor

Dear Colleagues,

As we are going to enter year 4 of the coronavirus pandemic, much progress has been made in developing prophylaxis and therapeutic agents against coronavirus infection. However, there are still many actual problems in the field of molecular mechanisms for coronavirus infection. Of them, the underlying molecular mechanism responsible for the high level of viral transmissibility and broad tissue tropism or interspecies transmission remains largely unexplored; the characterization of the coronavirus infection process, as well as viral and host factors that are involved in the pathogenesis of viral infection; the development of novel or repurposed prophylaxis and therapeutic agents targeting host-pathogen interaction; the molecular mechanism underlying the waning effectiveness of COVID vaccines or drugs and possible viral breakthrough infections and immune evasion, etc., warrant further investigation.

For this Special Issue, we are seeking original research or review articles that will improve our knowledge of these topics mentioned above.

Dr. Qibin Geng  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI